Entero Therapeutics (ENTO) got a $2 million revolving loan and appointed three new board members designated by the undisclosed lender as a condition for the funding.
Richard Paolone, Eric Corbett and Manpreet Uppal replaced James Sapirstein, Alastair Riddell and Timothy Ramdeen on the board, the company said Friday in a statement.
The board has five members. Sapirstein is chief executive officer of Entero.
Price: 0.55, Change: +0.03, Percent Change: +6.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.